Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Edward B, Reilly"'
Autor:
Mark G. Anderson, Qian Zhang, Luis E. Rodriguez, Claudie M. Hecquet, Cherrie K. Donawho, Peter J. Ansell, Edward B. Reilly
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Prolactin receptor (PRLR) is an attractive antibody therapeutic target with expression across a broad population of breast cancers. Antibody efficacy, however, may be limited to subtypes with either PRLR overexpression and/or thos
Externí odkaz:
https://doaj.org/article/d252c24e196e4c3ab83f1b6ec0dc1194
Autor:
Ghazal Naseri Kouzehgarani, Pankaj Kumar, Susan E. Bolin, Edward B. Reilly, Didier R. Lefebvre
Publikováno v:
Pharmaceutics, Vol 14, Iss 7, p 1441 (2022)
Cerebrospinal fluid (CSF) microcirculation refers to CSF flow through brain or spinal parenchyma. CSF enters the tissue along the perivascular spaces of the penetrating arteries where it mixes with the interstitial fluid circulating through the extra
Externí odkaz:
https://doaj.org/article/4a54b6351d0c4b0d8daf9e39fdb688a2
Autor:
Maissa Mhibik, Erika M Gaglione, David Eik, John Herrick, Janet Le, Inhye E Ahn, Christopher Chiu, Monica Wielgos-Bonvallet, Ida H Hiemstra, Esther CW Breij, Jenny Chen, Edward B Reilly, Pearlie K. Epling-Burnette, Edith Szafer Glusman, Clare Sun, Adrian Wiestner
Publikováno v:
Blood Advances.
Chronic lymphocytic leukemia (CLL) is an immunosuppressive disease characterized by increased infectious morbidity and inferior anti-tumor activity of immunotherapies. Targeted therapy with Bruton's tyrosine kinase inhibitors (BTKis), or the Bcl-2 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcae76acd97efcd6a93cfb0fc7587566
https://doi.org/10.1182/bloodadvances.2022009517
https://doi.org/10.1182/bloodadvances.2022009517
Autor:
Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal tissue expression represents a significant toxicity risk. The anti-EGFR antibody ABT-806 targets a unique tumor-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7af9a53ea623c6dab8499fd2219a76bc
https://doi.org/10.1158/1535-7163.c.6538540.v1
https://doi.org/10.1158/1535-7163.c.6538540.v1
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Amino Acid Sequence of AM-1 VH Region
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4690d3c6ba234726f181827c74d28b66
https://doi.org/10.1158/1535-7163.22505197
https://doi.org/10.1158/1535-7163.22505197
Autor:
Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Table S1: Mouse Strains Used for Xenograft Studies; Table S2: ABT-414 Growth Inhibition of Xenograft Tumors; Figure S1: Efficacy of ABT-414, ABT-806-vcMMAE, and unconjugated MMAE co-dosed with ABT-806 in U87MGde2-7 Tumor-Bearing Mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161f204be3c985a50dfa14ac1e0540f9
https://doi.org/10.1158/1535-7163.22506979
https://doi.org/10.1158/1535-7163.22506979
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead. Depatux-m has demonstrated promising clinical activity in glio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::313f2d242d9ae4aea09b4db055c77042
https://doi.org/10.1158/1535-7163.c.6537985.v1
https://doi.org/10.1158/1535-7163.c.6537985.v1
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson
In vivo Efficacy of ABBV-321 tumor targeting.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677c6299c1714e54b6ad5827987299cc
https://doi.org/10.1158/1535-7163.22518654
https://doi.org/10.1158/1535-7163.22518654
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson
ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d6b8106485307d7fd6d8f1fb1b654d
https://doi.org/10.1158/1535-7163.c.6542049
https://doi.org/10.1158/1535-7163.c.6542049
Autor:
Edward B. Reilly, Louie Naumovski, Joann P. Palma, Edward K. Han, Qian Zhang, Lora Tucker, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Mark G. Anderson, Jieyi Wang
Purpose: Despite the importance of the MET oncogene in many malignancies, clinical strategies targeting c-Met have benefitted only small subsets of patients with tumors driven by signaling through the c-Met pathway, thereby necessitating selection of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7da2bd78ea69eb0cc09b70d81041cc0c
https://doi.org/10.1158/1078-0432.c.6526458
https://doi.org/10.1158/1078-0432.c.6526458